ImmunityBio on February 18th had a trading volume of $615 million, a 594.08% increase compared to the previous trading day.

2026-02-19 03:32:35

Abstract generation in progress

On February 18, 2026, ImmunityBio (IBRX) had a trading volume of $615 million, ranking 189th among U.S. stocks for the day, with a 594.08% increase compared to yesterday. The trading volume for the day was 79.2292 million shares.

ImmunityBio (IBRX) rose 41.86% on February 18, 2026, closing at $8.54. The stock increased by 30.58% over the past five trading days, 36.64% for the entire month of February, 331.31% since the beginning of the year, and 154.93% over the past 52 weeks.

*If the company has been listed for less than 52 weeks, the 52-week change is calculated from the listing date to now (this also applies to listings of less than one month or fewer than five trading days).

ImmunityBio (IBRX)	Trading Volume / USD	Change from Yesterday	Shares Traded
February 18, 2026	$615 million	594.08%	79.2292 million
February 17, 2026	$88.6683 million	-65.83%	14.6228 million
February 13, 2026	$259 million	189.40%	39.436 million
February 12, 2026	$89.655 million	-19.43%	13.4491 million
February 11, 2026	$111 million	-26.43%	17.179 million

ImmunityBio released its Q3 FY2025 financial report (cumulative) on November 5, 2025. Revenue from January 1 to September 30, 2025, was $75.003 million, a year-over-year increase of 942.72%. Net loss was $290 million, narrowing by 18.32% year-over-year.

ImmunityBio, Inc. was incorporated on October 7, 2002, under the name ZelleRx Corporation in Illinois, and on January 22, 2010, the company was renamed Conkwest Inc. ImmunityBio is a leading late-stage immunotherapy company that activates innate and adaptive immune systems to address unmet needs in oncology and infectious diseases. The company is a leading manufacturer of off-the-shelf natural killer (NK) cell therapies, including memory NK cells, combined with antibody-cytokine fusion proteins, albumin-binding immunomodulators, and vaccine vectors. By integrating these NK, macrophage, and T-cell activation platforms, the company believes ImmunityBio is at the forefront of immunotherapy, with late-stage clinical development across multiple tumor types and infectious diseases.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes